DexCom, Inc. (NASDAQ:DXCM) Position Cut by Rafferty Asset Management LLC

Rafferty Asset Management LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCMFree Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,589 shares of the medical device company’s stock after selling 387 shares during the quarter. Rafferty Asset Management LLC’s holdings in DexCom were worth $15,833,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Stableford Capital II LLC boosted its stake in DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares in the last quarter. D Orazio & Associates Inc. boosted its stake in DexCom by 0.8% during the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after purchasing an additional 98 shares in the last quarter. Valley National Advisers Inc. boosted its stake in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Finally, FORVIS Wealth Advisors LLC boosted its stake in DexCom by 0.7% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after purchasing an additional 110 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 1.3 %

Shares of NASDAQ:DXCM traded up $1.48 during midday trading on Tuesday, hitting $116.71. 2,904,354 shares of the stock were exchanged, compared to its average volume of 2,917,224. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The business’s fifty day simple moving average is $131.49 and its two-hundred day simple moving average is $125.65. The company has a market capitalization of $46.41 billion, a PE ratio of 74.34, a P/E/G ratio of 2.90 and a beta of 1.22.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, research analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Raymond James increased their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Finally, StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Sunday. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.94.

Read Our Latest Research Report on DXCM

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now directly owns 68,212 shares in the company, valued at $8,611,765. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at $8,611,765. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at $36,816,646.33. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 187,293 shares of company stock worth $25,295,452. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.